These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25078308)

  • 1. Hepatitis C beware--the end is nigh.
    Gane E
    Lancet; 2014 Nov; 384(9954):1557-60. PubMed ID: 25078308
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir.
    Ozaras R; Mete B; Yemisen M; Balkan II; Alkan M; Tabak F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):393-4. PubMed ID: 26405716
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b: a case report].
    Pi SN; Chen YP
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(8):1163-4. PubMed ID: 27578593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case of psoriatic patient who maintains long-term remission after anti-hepatitis C virus agents and ustekinumab treatment.
    Kikuchi S; Umezawa Y; Chihara M; Asahina A; Nakagawa H
    J Dermatol; 2018 Mar; 45(3):e59-e60. PubMed ID: 29388245
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
    Toyoda H; Kumada T; Tada T; Takaguchi K; Ishikawa T; Tsuji K; Zeniya M; Iio E; Tanaka Y
    J Gastroenterol; 2016 Jul; 51(7):741-7. PubMed ID: 26872889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
    Morisawa N; Koshima Y; Satoh JI; Maruyama Y; Kuriyama S; Yokoo T; Amemiya M
    Clin Exp Nephrol; 2017 Oct; 21(5):818-824. PubMed ID: 27771774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
    Nam HC; Lee HL; Yang H; Song MJ
    Clin Mol Hepatol; 2016 Jun; 22(2):259-66. PubMed ID: 27377910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological properties and clinical efficacy of daclatasvir (Daklinza®) and asunaprevir (Sunvepra®)].
    Amano M; Ishikawa H
    Nihon Yakurigaku Zasshi; 2015 Mar; 145(3):152-62. PubMed ID: 25765498
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
    Wei L; Zhang M; Xu M; Chuang WL; Lu W; Xie W; Jia Z; Gong G; Li Y; Bae SH; Yang YF; Xie Q; Lin S; Chen X; Niu J; Jia J; Garimella T; Torbeyns A; McPhee F; Treitel M; Yin PD; Mo L
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1860-1867. PubMed ID: 27003037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.
    Uojima H; Murakami S; Nakatani S; Hidaka H; Takeuchi A; Tanaka Y; Inoue T; Yamane K; Kubota K; Nakazawa T; Shibuya A; Tanaka Y; Koizumi W
    Intern Med; 2018 Apr; 57(7):951-956. PubMed ID: 29225269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life.
    Kawakubo M; Eguchi Y; Okada M; Iwane S; Oeda S; Otsuka T; Nakashita S; Araki N; Koga A
    Intern Med; 2018 Jul; 57(14):1959-1966. PubMed ID: 29526929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
    Koshino K; Ushigome H; Masuda K; Matsuyama T; Harada S; Nakamura T; Nobori S; Iida T; Yoshimura N
    Transplant Proc; 2017 Jun; 49(5):1053-1055. PubMed ID: 28583525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continued progress against hepatitis C infection.
    Conjeevaram H
    JAMA; 2015 May; 313(17):1716-7. PubMed ID: 25942721
    [No Abstract]   [Full Text] [Related]  

  • 16. [Daclatasvir plus asunaprevir combination therapy for patients with chronic hepatitis C].
    Suzuki F
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():257-61. PubMed ID: 26845941
    [No Abstract]   [Full Text] [Related]  

  • 17. Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
    Barrail-Tran A; Vincent C; Furlan V; Rosa I; Rosenthal E; Cheret A; Molina JM; Taburet AM; Piroth L;
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7903-5. PubMed ID: 26438504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
    Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
    Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.
    Hirashima N; Iwase H; Shimada M; Ryuge N; Imamura J; Ikeda H; Tanaka Y; Matsumoto N; Okuse C; Itoh F; Yokomaku Y; Watanabe T
    Clin J Gastroenterol; 2017 Feb; 10(1):41-46. PubMed ID: 27766544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.